Protacs |
The 357-page report ‘Targeted
Protein Degradation Market: Focus on Technology Platforms and Therapeutics,
2020-2030’ focuses on the small molecule degraders including specific
and non-genetic IAP-dependent protein erasers (SNIPERs), proteolysis
targeting chimeras (PROTACs), lysosome targeting chimeras
(LYTACs), endosome targeting chimeras (ENDTACs), epichaperome inhibitors,
hydrophobic tags, immuno-modulatory imide drugs (IMiDs), protein homeostatic
modulators, selective androgen receptor degraders (SARDs), selective estrogen receptor
degraders (SERDs), and specific bromodomain and extra-terminal motif (BET)
inhibitors and deubiquitinase (DUB) inhibitors. The report highlights the
capabilities of protein degraders and major market players involved in the
evaluation. It is worth mentioning that there is no protein-degrader based drug
in the market yet. We can expect the therapy to become an extensive part of
therapeutic modality in upcoming decade.
Comments
Post a Comment